Busulfan

Generic Name
Busulfan
Brand Names
Busulfex, Myleran, Busulfan Fresenius Kabi
Drug Type
Small Molecule
Chemical Formula
C6H14O6S2
CAS Number
55-98-1
Unique Ingredient Identifier
G1LN9045DK
Background

Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about. According t...

Indication

For use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous (myeloid, myelocytic, granulocytic) leukemia (FDA has designated busulfan as an orphan drug for this use). It is also used as a component of pretransplant conditioning regimens in patients undergoing...

Associated Conditions
Chronic Myelogenous Leukemia (CML), Essential Thrombocythemia (ET), Polycythemia Vera (PV)
Associated Therapies
Conditioning regimens for allogeneic stem cell transplantation therapy
Clinical Trials
Related News

Chemotherapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory AIDS-Related Lymphoma

Phase 2
Completed
Conditions
Lymphoma
First Posted Date
2003-01-27
Last Posted Date
2016-02-03
Lead Sponsor
AIDS Malignancy Consortium
Registration Number
NCT00005824
Locations
🇺🇸

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

🇺🇸

Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

Combination Chemotherapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloproliferative Disorders

First Posted Date
2003-01-27
Last Posted Date
2010-04-02
Lead Sponsor
Fred Hutchinson Cancer Center
Target Recruit Count
20
Registration Number
NCT00002792
Locations
🇺🇸

Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Chemotherapy, Interferon, and Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia

Phase 3
Conditions
Leukemia
First Posted Date
2003-01-27
Last Posted Date
2013-08-02
Lead Sponsor
German CML Study Group
Target Recruit Count
750
Registration Number
NCT00002771
Locations
🇩🇪

III Medizinische Klinik Mannheim, Mannheim, Germany

Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma

First Posted Date
2003-01-27
Last Posted Date
2014-06-24
Lead Sponsor
University of Leicester
Target Recruit Count
1200
Registration Number
NCT00020566
Locations
🇺🇸

University of Chicago Cancer Research Center, Chicago, Illinois, United States

🇺🇸

Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States

🇺🇸

West Virginia University Health Sciences Center - Charleston, Charleston, West Virginia, United States

and more 100 locations

Combination Chemotherapy With or Without Filgrastim Before Surgery, High-Dose Chemotherapy, and Radiation Therapy Followed by Isotretinoin With or Without Monoclonal Antibody in Treating Patients With Neuroblastoma

Phase 3
Conditions
Neuroblastoma
First Posted Date
2003-01-27
Last Posted Date
2014-06-24
Lead Sponsor
University of Leicester
Target Recruit Count
175
Registration Number
NCT00030719
Locations
🇧🇪

Universitair Ziekenhuis Gent, Ghent, Belgium

🇳🇴

Rikshospitalet University Hospital, Oslo, Norway

🇬🇧

Birmingham Children's Hospital, Birmingham, England, United Kingdom

and more 28 locations

Busulfan and Etoposide Followed by Peripheral Blood Stem Cell Transplant and Low-Dose Aldesleukin in Treating Patients With Acute Myeloid Leukemia

First Posted Date
2003-01-27
Last Posted Date
2017-06-05
Lead Sponsor
Fred Hutchinson Cancer Center
Target Recruit Count
30
Registration Number
NCT00003875
Locations
🇺🇸

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

High-Dose Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

First Posted Date
2003-01-27
Last Posted Date
2010-06-11
Lead Sponsor
Case Comprehensive Cancer Center
Target Recruit Count
66
Registration Number
NCT00003116
Locations
🇺🇸

Ireland Cancer Center at University Hosptials Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Pilot Study Of Unrelated UCB Transplant for Non-Malignant Hematologic Conditions

First Posted Date
2003-01-27
Last Posted Date
2010-06-11
Lead Sponsor
Case Comprehensive Cancer Center
Target Recruit Count
6
Registration Number
NCT00003336
Locations
🇺🇸

Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Combination Chemotherapy, Peripheral Stem Cell Transplantation, and Biological Therapy in Treating Patients With Solid Tumors or Lymphoma

First Posted Date
2003-01-27
Last Posted Date
2010-05-14
Lead Sponsor
Fred Hutchinson Cancer Center
Registration Number
NCT00027937
Locations
🇺🇸

Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome

Phase 2
Completed
Conditions
Leukemia
Myelodysplastic Syndromes
First Posted Date
2003-01-27
Last Posted Date
2010-05-13
Lead Sponsor
Fred Hutchinson Cancer Center
Registration Number
NCT00024050
Locations
🇺🇸

Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy